Shares of Ultragenyx Pharmaceutical (RARE) surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.
Analyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.
Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company has several promising drug candidates in its pipeline, and Werber's report likely highlighted the potential for these therapies to drive future growth and profitability for the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。